{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T02:49:59Z","timestamp":1785034199450,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T00:00:00Z","timestamp":1518825600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This work was supported in part by an innovation pool grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00432-018-2609-5","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T21:23:30Z","timestamp":1518816210000},"page":"865-874","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features"],"prefix":"10.1007","volume":"144","author":[{"given":"Markus","family":"Rechsteiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Dedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Pestalozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Sobottka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Moch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2855-983X","authenticated-orcid":false,"given":"Zsuzsanna","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,17]]},"reference":[{"key":"2609_CR1","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1634\/theoncologist.2013-0039","volume":"18","author":"P Chalasani","year":"2013","unstructured":"Chalasani P, Livingston R (2013) Differential chemotherapeutic sensitivity for breast tumors with \u201cBRCAness\u201d: a review. Oncologist 18:909\u2013916","journal-title":"Oncologist"},{"key":"2609_CR2","unstructured":"Dabbs DJ (2016) Breast Pathology, 2nd edn, ISBN: 9780323462365, ISBN: 9780323462372, ISBN: 9780323389617, Elsevier, p 848"},{"key":"2609_CR3","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1093\/annonc\/mdv278","volume":"26","author":"DM Eccles","year":"2015","unstructured":"Eccles DM, Mitchell G, Monteiro AN, Schmutzler R, Couch FJ, Spurdle AB, Gomez-Garcia EB, Group ECW (2015) Brca1 and brca2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. Ann Oncol 26:2057\u20132065","journal-title":"Ann Oncol"},{"key":"2609_CR4","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1158\/0008-5472.CAN-07-1587","volume":"68","author":"DJ Farrugia","year":"2008","unstructured":"Farrugia DJ, Agarwal MK, Pankratz VS, Deffenbaugh AM, Pruss D, Frye C, Wadum L, Johnson K, Mentlick J, Tavtigian SV et al (2008) Functional assays for classification of brca2 variants of uncertain significance. Cancer Res 68:3523\u20133531","journal-title":"Cancer Res"},{"key":"2609_CR5","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-10-2560","volume":"17","author":"AM Gonzalez-Angulo","year":"2011","unstructured":"Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK et al (2011) Incidence and outcome of brca mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17:1082\u20131089","journal-title":"Clin Cancer Res"},{"key":"2609_CR6","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1186\/s12885-016-2848-2","volume":"16","author":"E Gross","year":"2016","unstructured":"Gross E, van Tinteren H, Li Z, Raab S, Meul C, Avril S, Laddach N, Aubele M, Propping C, Gkazepis A et al (2016) Identification of brca1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of brca1-associated chromosomal regions: a validation study. BMC Cancer 16:811","journal-title":"BMC Cancer"},{"key":"2609_CR7","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","volume":"28","author":"BT Hennessy","year":"2010","unstructured":"Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD, 2nd, Abkevich V, Potter J, Pruss D, Glenn P et al (2010) Somatic mutations in brca1 and brca2 could expand the number of patients that benefit from poly (adp ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 28:3570\u20133576","journal-title":"J Clin Oncol"},{"key":"2609_CR8","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.1200\/JCO.2010.28.0719","volume":"28","author":"JS Kwon","year":"2010","unstructured":"Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, Arun B (2010a) Expanding the criteria for brca mutation testing in breast cancer survivors. J Clin Oncol 28:4214\u20134220","journal-title":"J Clin Oncol"},{"key":"2609_CR9","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1200\/JCO.2008.21.4684","volume":"28","author":"JS Kwon","year":"2010","unstructured":"Kwon JS, Daniels MS, Sun CC, Lu KH (2010b) Preventing future cancers by testing women with ovarian cancer for brca mutations. J Clin Oncol 28:675\u2013682","journal-title":"J Clin Oncol"},{"key":"2609_CR10","volume-title":"Who classification of tumours of the breast, fourth edition 2012","author":"SREISS Lakhani","year":"2012","unstructured":"Lakhani SREISS, Tan PH, van de Vijver MJ (2012) Who classification of tumours of the breast, fourth edition 2012. International Agency for Research on Cancer, Lyon"},{"issue":"5","key":"2609_CR11","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1158\/1078-0432.CCR-16-0198","volume":"23","author":"EH Lips","year":"2017","unstructured":"Lips EH, Debipersad RD, Scheerman CE, Mulder L, Sonke GS, van der Kolk LE, Wesseling J, Hogervorst FB, Nederlof PM (2017) BRCA1-mutated estrogen receptor-positive breast cancer shows BRCAness, suggesting sensitivity to drugs targeting homologous recombination deficiency. Clin Cancer Res 23(5):1236\u20131241","journal-title":"Clin Cancer Res"},{"key":"2609_CR12","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.18632\/oncotarget.6834","volume":"7","author":"A Mafficini","year":"2016","unstructured":"Mafficini A, Simbolo M, Parisi A, Rusev B, Luchini C, Cataldo I, Piazzola E, Sperandio N, Turri G, Franchi M et al (2016) Brca somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing. Oncotarget 7:1076\u20131083","journal-title":"Oncotarget"},{"key":"2609_CR13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/jso.24367","volume":"114","author":"AM Mateo","year":"2016","unstructured":"Mateo AM, Pezzi TA, Sundermeyer M, Kelley CA, Klimberg VS, Pezzi CM (2016) Atypical medullary carcinoma of the breast has similar prognostic factors and survival to typical medullary breast carcinoma: 3976 cases from the national cancer data base. J Surg Oncol 114:533\u2013536","journal-title":"J Surg Oncol"},{"key":"2609_CR14","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","volume":"21","author":"N Mavaddat","year":"2012","unstructured":"Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M et al (2012) Pathology of breast and ovarian cancers among brca1 and brca2 mutation carriers: Results from the consortium of investigators of modifiers of brca1\/2 (cimba). Cancer Epidemiol Biomark Prev 21:134\u2013147","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2609_CR15","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/annonc\/mdw142","volume":"27","author":"M Moschetta","year":"2016","unstructured":"Moschetta M, George A, Kaye SB, Banerjee S (2016) Brca somatic mutations and epigenetic brca modifications in serous ovarian cancer. Ann Oncol 27:1449\u20131455","journal-title":"Ann Oncol"},{"key":"2609_CR16","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/annonc\/mdp055","volume":"20","author":"F Muggia","year":"2009","unstructured":"Muggia F (2009) Brca-deficient animal models and cisplatin resistance. Ann Oncol 20:962","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"2609_CR17","doi-asserted-by":"publisher","first-page":"i7","DOI":"10.1093\/annonc\/mdq659","volume":"22","author":"F Muggia","year":"2011","unstructured":"Muggia F, Safra T, Dubeau L (2011) Brca genes: lessons learned from experimental and clinical cancer. Ann Oncol 22(Suppl 1):i7\u2013i10","journal-title":"Ann Oncol"},{"key":"2609_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","volume":"16","author":"AM Oza","year":"2015","unstructured":"Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Spacek J, Vuylsteke P, Hirte H et al (2015) Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 16:87\u201397","journal-title":"Lancet Oncol"},{"key":"2609_CR19","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/humu.20880","volume":"29","author":"SE Plon","year":"2008","unstructured":"Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, Hogervorst FB, Hoogerbrugge N, Spurdle AB, Tavtigian SV et al (2008) Sequence variant classification and reporting: Recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29:1282\u20131291","journal-title":"Hum Mutat"},{"key":"2609_CR20","first-page":"3445","volume":"30","author":"K Rhiem","year":"2010","unstructured":"Rhiem K, Todt U, Wappenschmidt B, Klein A, Wardelmann E, Schmutzler RK (2010) Sporadic breast carcinomas with somatic brca1 gene deletions share genotype\/phenotype features with familial breast carcinomas. Anticancer Res 30:3445\u20133449","journal-title":"Anticancer Res"},{"key":"2609_CR21","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/humu.20896","volume":"29","author":"SV Tavtigian","year":"2008","unstructured":"Tavtigian SV, Byrnes GB, Goldgar DE, Thomas A (2008) Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications. Hum Mutat 29:1342\u20131354","journal-title":"Hum Mutat"},{"key":"2609_CR22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1186\/1471-2407-13-615","volume":"13","author":"Z Varga","year":"2013","unstructured":"Varga Z, Noske A, Ramach C, Padberg B, Moch H (2013) Assessment of her2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study. BMC Cancer 13:615","journal-title":"BMC Cancer"},{"key":"2609_CR23","doi-asserted-by":"publisher","first-page":"e105961","DOI":"10.1371\/journal.pone.0105961","volume":"9","author":"Z Varga","year":"2014","unstructured":"Varga Z, Tubbs RR, Moch H (2014) Concomitant detection of her2 protein and gene alterations by immunohistochemistry (ihc) and silver enhanced in situ hybridization (sish) identifies her2 positive breast cancer with and without gene amplification. PLoS One 9:e105961","journal-title":"PLoS One"},{"key":"2609_CR24","doi-asserted-by":"publisher","first-page":"R47","DOI":"10.1186\/bcr3655","volume":"16","author":"MA Vollebergh","year":"2014","unstructured":"Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Wesseling J, Vd Vijver MJ, de Vries EG, van Tinteren H, Jonkers J, Hauptmann M et al (2014) Genomic patterns resembling brca1- and brca2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res 16:R47","journal-title":"Breast Cancer Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-018-2609-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2609-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2609-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,16]],"date-time":"2019-02-16T22:35:03Z","timestamp":1550356503000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-018-2609-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,17]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["2609"],"URL":"https:\/\/doi.org\/10.1007\/s00432-018-2609-5","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,17]]},"assertion":[{"value":"30 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}